Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation

Dario Pasalic, Halena M. Gazelka, Rachel J. Topazian, Lillian C. Buchhalter, Abigale L. Ottenberg, Tracy L. Webster, Keith M. Swetz, Paul Mueller

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The presence of cardiac pacemakers and defibrillators complicates making end-of-life (EOL) medical decisions. Palliative care/medicine consultation (PCMC) may benefit patients and primary providers, but data are lacking. We retrospectively reviewed 150 charts of patients who underwent device deactivation at our tertiary care center (between November 1, 2008, and September 1, 2012), assessing for PCMC and outcomes. Overall, 42% of patients received a PCMC, and 68% of those PCMCs specifically addressed device deactivation. Median survival following deactivation was 2 days, with 42% of deaths occurring within 1 day of deactivation. There was no difference in survival between the groups. The EOL care for patients with implanted cardiac devices is complex, but PCMC may assist with symptom management and clarification of goals of care for such patients.

Original languageEnglish (US)
Pages (from-to)966-971
Number of pages6
JournalAmerican Journal of Hospice and Palliative Medicine
Volume33
Issue number10
DOIs
StatePublished - Dec 1 2016

Fingerprint

Terminal Care
Implantable Defibrillators
Palliative Care
Referral and Consultation
Equipment and Supplies
Patient Care Planning
Defibrillators
Survival
Tertiary Care Centers
Palliative Medicine

Keywords

  • cardiac pacemaker
  • cardiovascular implantable electronic device
  • end of life
  • implantable cardioverter-defibrillator
  • medical ethics
  • palliative care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation. / Pasalic, Dario; Gazelka, Halena M.; Topazian, Rachel J.; Buchhalter, Lillian C.; Ottenberg, Abigale L.; Webster, Tracy L.; Swetz, Keith M.; Mueller, Paul.

In: American Journal of Hospice and Palliative Medicine, Vol. 33, No. 10, 01.12.2016, p. 966-971.

Research output: Contribution to journalArticle

Pasalic, Dario ; Gazelka, Halena M. ; Topazian, Rachel J. ; Buchhalter, Lillian C. ; Ottenberg, Abigale L. ; Webster, Tracy L. ; Swetz, Keith M. ; Mueller, Paul. / Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation. In: American Journal of Hospice and Palliative Medicine. 2016 ; Vol. 33, No. 10. pp. 966-971.
@article{6bc58907565a413e85cd2472ced3796a,
title = "Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation",
abstract = "The presence of cardiac pacemakers and defibrillators complicates making end-of-life (EOL) medical decisions. Palliative care/medicine consultation (PCMC) may benefit patients and primary providers, but data are lacking. We retrospectively reviewed 150 charts of patients who underwent device deactivation at our tertiary care center (between November 1, 2008, and September 1, 2012), assessing for PCMC and outcomes. Overall, 42{\%} of patients received a PCMC, and 68{\%} of those PCMCs specifically addressed device deactivation. Median survival following deactivation was 2 days, with 42{\%} of deaths occurring within 1 day of deactivation. There was no difference in survival between the groups. The EOL care for patients with implanted cardiac devices is complex, but PCMC may assist with symptom management and clarification of goals of care for such patients.",
keywords = "cardiac pacemaker, cardiovascular implantable electronic device, end of life, implantable cardioverter-defibrillator, medical ethics, palliative care",
author = "Dario Pasalic and Gazelka, {Halena M.} and Topazian, {Rachel J.} and Buchhalter, {Lillian C.} and Ottenberg, {Abigale L.} and Webster, {Tracy L.} and Swetz, {Keith M.} and Paul Mueller",
year = "2016",
month = "12",
day = "1",
doi = "10.1177/1049909115595017",
language = "English (US)",
volume = "33",
pages = "966--971",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation

AU - Pasalic, Dario

AU - Gazelka, Halena M.

AU - Topazian, Rachel J.

AU - Buchhalter, Lillian C.

AU - Ottenberg, Abigale L.

AU - Webster, Tracy L.

AU - Swetz, Keith M.

AU - Mueller, Paul

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The presence of cardiac pacemakers and defibrillators complicates making end-of-life (EOL) medical decisions. Palliative care/medicine consultation (PCMC) may benefit patients and primary providers, but data are lacking. We retrospectively reviewed 150 charts of patients who underwent device deactivation at our tertiary care center (between November 1, 2008, and September 1, 2012), assessing for PCMC and outcomes. Overall, 42% of patients received a PCMC, and 68% of those PCMCs specifically addressed device deactivation. Median survival following deactivation was 2 days, with 42% of deaths occurring within 1 day of deactivation. There was no difference in survival between the groups. The EOL care for patients with implanted cardiac devices is complex, but PCMC may assist with symptom management and clarification of goals of care for such patients.

AB - The presence of cardiac pacemakers and defibrillators complicates making end-of-life (EOL) medical decisions. Palliative care/medicine consultation (PCMC) may benefit patients and primary providers, but data are lacking. We retrospectively reviewed 150 charts of patients who underwent device deactivation at our tertiary care center (between November 1, 2008, and September 1, 2012), assessing for PCMC and outcomes. Overall, 42% of patients received a PCMC, and 68% of those PCMCs specifically addressed device deactivation. Median survival following deactivation was 2 days, with 42% of deaths occurring within 1 day of deactivation. There was no difference in survival between the groups. The EOL care for patients with implanted cardiac devices is complex, but PCMC may assist with symptom management and clarification of goals of care for such patients.

KW - cardiac pacemaker

KW - cardiovascular implantable electronic device

KW - end of life

KW - implantable cardioverter-defibrillator

KW - medical ethics

KW - palliative care

UR - http://www.scopus.com/inward/record.url?scp=84994138716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994138716&partnerID=8YFLogxK

U2 - 10.1177/1049909115595017

DO - 10.1177/1049909115595017

M3 - Article

C2 - 26169518

AN - SCOPUS:84994138716

VL - 33

SP - 966

EP - 971

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 10

ER -